Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.

Long-term follow-up of the OPTIMISMM trial investigating pomalidomide-bortezomib-dexamethasone versus bortezomib-dexamethasone demonstrated a slight trend toward OS benefit (35.6 vs. 31.6 months, HR=0.94, 95% CI: 0.77-1.15; not statistically significant). 23 , 24 These findings combined with the clinically meaningful OS benefit demonstrated in ICARIA-MM with the Isa-Pd combination indicate the value of treating patients with RRMM using a regimen that includes pomalidomide and a monoclonal antibody.

also in 4,078 other papers